GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
GT Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.69−0.34 (-4.84%)
Close on Oct 19, 2026
- Market cap
- $259.71M
- P/E (TTM)
- –
- Dividend yield
- –
GT Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Market Cap | $301.78M | $166.30M |
| Enterprise Value | $294.97M | $88.19M |
| PB Ratio | 52.15 | 2.03 |
| P/TBV Ratio | 52.15 | 2.29 |
Income (trailing twelve months)
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Operating Income | -$16.34M | -$21.40M |
| Net Income | -$4.76M | -$22.46M |
| EBITDA | -$16.34M | -$16.91M |
Returns
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -231.2% | -53.2% |
| Return on Assets (ROA) | -77.2% | -40.9% |
| Return on Capital Employed (ROCE) | -282.3% | -38.1% |
Balance sheet
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.81M | $61.43M |
| Net Cash (Debt) | $6.81M | $15.35M |
| Net Cash Per Share | $0.15 | $0.66 |
| Equity (Book Value) | $5.79M | $49.09M |
| Book Value Per Share | $0.13 | $1.37 |
| Tangible Book Value | $5.79M | $23.52M |
| Working Capital | $5.79M | $76.81M |
Financial position
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Current Ratio | 3.50 | 3.34 |
| Quick Ratio | 2.94 | 2.44 |
Cash flow (trailing twelve months)
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.43M | -$12.35M |
Efficiency
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Profits Per Employee | -$4.76M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -1.58% | -23.3% |
Shares
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 45,109,500 | 58,127,000 |
| Shares Change (QoQ) | 321.9% | 0.54% |
| Float | 44,253,300 | 49,136,700 |
| Shares Held by Insiders | 1.90% | 11.6% |
Scores
| Measure | GT Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -52.74 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from GT Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.